Institute for Cancer Research at Oslo University Hospital
Represented by the Taskén group and Kjetil Tasken, MD, PhD, Professor of Medicine, Head of Institute for Cancer Research at Oslo University Hospital. Taskén is former director of the Centre for Molecular Medicine Norway (NCMM) at the University of Oslo, part of the Nordic EMBL Partnership. He was also the director of the Biotechnology Centre of Oslo from 2003-2016. He is the director for Norway of the ESFRI infrastructures EU-OPENSCREEN (academic chemical biology and screening) and EATRIS (translational medicine) and in charge of the corresponding national infrastructures.
Bioinformatics Core Facility at Oslo University Hospital and University of Oslo
Represented by The Hovig group and prof. Eivind Hovig, Cand. Real and Dr. philos from the University of Oslo, general genetics. Prof. Hovig serves as group leader at the Institute for Cancer Research, the Norwegian Radium Hospital and is adjunct professor at the Department of Informatics, University of Oslo. He is also co-PI and leader of bioinformatics in the Norwegian Cancer Genomics Consortium, partner in BigMed, a research project funded by the Research Council of Norway, as well as scientific head of the Bioinformatics Core Facility, funded by Helse Sør-Øst Regional Health Organisation.
Drug Discovery Laboratory AS
Represented by prof. Jo Klaveness is a professor of medical chemistry at the University of Oslo’s School of Pharmacy and the founder of Drug Discovery Laboratory AS. He has a doctoral degree and a master’s degree in organic chemistry as well as an MSc Pharm. in pharmaceutical chemistry from the University of Oslo. He has held several positions in Nycomed, including as project manager and head of the R&D organisation, and served in several boards of directors, including for Pronova Biopharma ASA and Omegatri AS. Klaveness is the inventor of more than 160 patent families related to several pharmaceutical products that are on the market.
Clinical Study Partners:
As Norwegian clinical studies have been severely reduced in the last years we are pleased that several prominent Norwegian Hospitals has joined us as study partners.
Sealds study partners are the Institute of Cancer Research, Oslo University Hospital- the Norwegian Radium Hospital, The Gastro-Surgical Department at Oslo University Hospital – Rikshospitalet, The Clinical Cancer Research Unit, Department of Oncology at Oslo University Hospital-The Norwegian Radium Hospital and The Surgical Clinic, Haukeland University Hospital.
Our method development study is planned to be continued in a new clinical interventional trial at Oslo University Hospital-The Norwegian Radium Hospital.